The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

The CDC's vaccine advisory committee is set to meet for the first time since HHS Secretary Robert F. Kennedy Jr. dismissed ...

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

A virus that once filled pediatric hospital beds and terrified new parents is finally being pushed back—before babies are ...

On Wednesday, the eight new members of the CDC’s Advisory Committee on Immunization Practices will begin a 2-day meeting in ...

La., has come out critical of Robert F. | Sen. Bill Cassidy, M.D., R-La., has come out critical of Robert F. Kennedy Jr.’s ...

Dr Fiona Havers resigned from her role tracking viral epidemics for the CDC due to a lack of confidence in the current leadership.

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs ...